Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience (NAGE)
NASDAQ:NAGE
Total Valuation
Niagen Bioscience has a market cap or net worth of $548.27M. The enterprise value is $746.92M.
Market Cap$548.27M
Enterprise Value$746.92M
Share Statistics
Niagen Bioscience has 79,806,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding79,806,140
Owned by Insiders4.99%
Owned by Institutions0.76%
Financial Efficiency
Niagen Bioscience’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 14.53%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)14.53%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee957.66K
Profits Per Employee82.21K
Employee Count104
Asset Turnover1.46
Inventory Turnover4.14
Valuation Ratios
The current PE Ratio of Niagen Bioscience is 28.5. Niagen Bioscience’s PEG ratio is -0.22.
PE Ratio28.5
PS Ratio4.55
PB Ratio9.84
Price to Fair Value9.84
Price to FCF37.97
Price to Operating Cash Flow26.60
PEG Ratio-0.22
Income Statement
In the last 12 months, Niagen Bioscience had revenue of 99.60M and earned 8.55M in profits. Earnings per share was 0.10.
Revenue99.60M
Gross Profit61.59M
Operating Income7.73M
Pretax Income8.86M
Net Income8.55M
EBITDA9.21M
Earnings Per Share (EPS)0.10
Cash Flow
In the last 12 months, operating cash flow was 21.41M and capital expenditures -260.00K, giving a free cash flow of 21.15M billion.
Operating Cash Flow21.41M
Free Cash Flow21.15M
Free Cash Flow per Share0.26
Dividends & Yields
Niagen Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change-8.78%
50-Day Moving Average8.00
200-Day Moving Average8.85
Relative Strength Index (RSI)39.40
Average Volume (3m)1.12M
Important Dates
Niagen Bioscience upcoming earnings date is Mar 11, 2026, After Close (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 11, 2026
Ex-Dividend Date―
Financial Position
Niagen Bioscience as a current ratio of 3.57, with Debt / Equity ratio of 5.13%
Current Ratio3.57
Quick Ratio3.06
Debt to Market Cap0.00
Net Debt to EBITDA-4.54
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Niagen Bioscience has paid 305.00K in taxes.
Income Tax305.00K
Effective Tax Rate0.03
Enterprise Valuation
Niagen Bioscience EV to EBITDA ratio is 44.71, with an EV/FCF ratio of 34.47.
EV to Sales4.13
EV to EBITDA44.71
EV to Free Cash Flow34.47
EV to Operating Cash Flow34.00
Balance Sheet
Niagen Bioscience has $64.14M in cash and marketable securities with $3.06M in debt, giving a net cash position of $61.08M billion.
Cash & Marketable Securities$64.14M
Total Debt$3.06M
Net Cash$61.08M
Net Cash Per Share$0.77
Tangible Book Value Per Share$0.54
Margins
Gross margin is 63.62%, with operating margin of 7.76%, and net profit margin of 8.58%.
Gross Margin63.62%
Operating Margin7.76%
Pretax Margin8.89%
Net Profit Margin8.58%
EBITDA Margin9.25%
EBIT Margin7.76%
Analyst Forecast
The average price target for Niagen Bioscience is $16.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.33
Price Target Upside135.64% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast36.04%
EPS Growth Forecast1240.00%